department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Levomilnacipran Hydrochloride · pharmadog

pharmadog
drugs
Levomilnacipran Hydrochloride

drug

patient view →

levomilnacipran hydrochloride ER

Marketedupdated 2mo ago

by Prinston Pharmaceutical Inc

Approved

community read0 votes

indications

investigational

Major Depression

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Levomilnacipran Hydrochloride

generic

levomilnacipran hydrochloride

indication

Major Depressive Disorder

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 2, 2031

~4.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

May 23, 2032compositionUS 8865937
May 23, 2032compositionUS 8865937
May 23, 2032compositionUS 8865937
May 23, 2032compositionUS 8865937
Mar 2, 2031method-of-use (U-839)US 84815984.7y
Mar 2, 2031method-of-use (U-839)US 84815984.7y
Mar 2, 2031method-of-use (U-839)US 84815984.7y
Mar 2, 2031method-of-use (U-839)US 84815984.7y
Jan 11, 2026method-of-use (U-839)US RE43879
Jan 11, 2026method-of-use (U-839)US RE43879
Jan 11, 2026method-of-use (U-839)US RE43879
Jan 11, 2026method-of-use (U-839)US RE43879

FDA exclusivities (4)

Mar 24, 2026M-304Method (3y)
Mar 24, 2026M-304Method (3y)
Mar 24, 2026M-304Method (3y)
Mar 24, 2026M-304Method (3y)

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying levomilnacipran hydrochloride ER

phase3Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disordercompletedn=392